CompletedNCT00999219

A Study of FK199B to Compare Efficacy With Zolpidem by Polysomnography in Patients With Insomnia

Medication studyAges 20–65JapanBipolarity

The study in practice

Understand this study

Listed age limits: 20 years to 65 years.

Listed locations: Chūbu and 6 more locationsSee all locations and recruitment
Study phase: Phase 3

Study clarity

Study start dateMarch 2006

Recruitment status: Completed
Enrollment listed in the registry: 55
Sponsor: Astellas Pharma Inc
Sponsor type: Pharmaceutical company
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: Japan
Age range: From 20 Years to 65 Years
Official registry ID: NCT00999219
Official title: Show the full official title
FK199B (Zolpidem MR Tablet) Phase III Clinical Study - A Double-Blind, Crossover, Comparative Polysomnographic Study Using Zolpidem (Myslee®) as a Positive Control in Patients With Insomnia, Excluding Patients With Schizophrenia or Manic-Depressive Psychosis

Completed

Chūbu · Hokkaido · Kansai

4 more locations

FAQ

Who is behind this study?

The study sponsor is Astellas Pharma Inc, a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including FK199B and Zolpidem.

Who was this study for?

Listed age limits: 20 years to 65 years.

Explore other studies

Explore HopeStage studies by mental health topic and refine the results to suit your situation.